Följ
Alexa Schrock
Alexa Schrock
Okänd anknytning
Verifierad e-postadress på foundationmedicine.com
Titel
Citeras av
Citeras av
År
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
ZR Chalmers, CF Connelly, D Fabrizio, L Gay, SM Ali, R Ennis, A Schrock, ...
Genome medicine 9, 1-14, 2017
28792017
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma
F Skoulidis, ME Goldberg, DM Greenawalt, MD Hellmann, MM Awad, ...
Cancer discovery 8 (7), 822-835, 2018
12292018
Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer
AB Schrock, C Ouyang, J Sandhu, E Sokol, D Jin, JS Ross, VA Miller, ...
Annals of Oncology 30 (7), 1096-1103, 2019
5462019
Acquired Resistance to KRASG12C Inhibition in Cancer
MM Awad, S Liu, II Rybkin, KC Arbour, J Dilly, VW Zhu, ML Johnson, ...
New England Journal of Medicine 384 (25), 2382-2393, 2021
5292021
Characterization of 298 patients with lung cancer harboring MET exon 14 skipping alterations
AB Schrock, GM Frampton, J Suh, ZR Chalmers, M Rosenzweig, ...
Journal of Thoracic Oncology 11 (9), 1493-1502, 2016
3752016
Non-V600BRAF mutations define a clinically distinct molecular subtype of metastatic colorectal cancer
JC Jones, LA Renfro, HO Al-Shamsi, AB Schrock, A Rankin, BY Zhang, ...
Journal of Clinical Oncology 35 (23), 2624, 2017
3452017
Impact of EML4-ALK variant on resistance mechanisms and clinical outcomes in ALK-positive lung cancer
JJ Lin, VW Zhu, S Yoda, BY Yeap, AB Schrock, I Dagogo-Jack, NA Jessop, ...
Journal of Clinical Oncology 36 (12), 1199, 2018
2962018
Tumor mutational burden as a predictive biomarker for response to immune checkpoint inhibitors: a review of current evidence
SJ Klempner, D Fabrizio, S Bane, M Reinhart, T Peoples, SM Ali, ...
The oncologist 25 (1), e147-e159, 2020
2722020
Real-time targeted genome profile analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or used as biomarkers
AD Singhi, B George, JR Greenbowe, J Chung, J Suh, A Maitra, ...
Gastroenterology 156 (8), 2242-2253. e4, 2019
2622019
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer
F Pietrantonio, F Di Nicolantonio, AB Schrock, J Lee, S Tejpar, ...
Journal of the National Cancer Institute 109 (12), djx089, 2017
2302017
Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition
DA Fabrizio, TJ George Jr, RF Dunne, G Frampton, J Sun, K Gowen, ...
Journal of gastrointestinal oncology 9 (4), 610, 2018
2272018
Structure-based classification predicts drug response in EGFR-mutant NSCLC
JP Robichaux, X Le, RSK Vijayan, JK Hicks, S Heeke, YY Elamin, HY Lin, ...
Nature 597 (7878), 732-737, 2021
2222021
Diverse EGFR exon 20 insertions and co-occurring molecular alterations identified by comprehensive genomic profiling of NSCLC
JW Riess, DR Gandara, GM Frampton, R Madison, N Peled, JA Bufill, ...
Journal of Thoracic Oncology 13 (10), 1560-1568, 2018
2152018
Comprehensive genomic profiling of 282 pediatric low‐and high‐grade gliomas reveals genomic drivers, tumor mutational burden, and hypermutation signatures
A Johnson, E Severson, L Gay, JA Vergilio, J Elvin, J Suh, S Daniel, ...
The oncologist 22 (12), 1478-1490, 2017
2042017
Total mutation burden (TMB) in lung cancer (LC) and relationship with response to PD-1/PD-L1 targeted therapies.
DR Spigel, AB Schrock, D Fabrizio, GM Frampton, J Sun, J He, K Gowen, ...
Journal of Clinical Oncology 34 (15_suppl), 9017-9017, 2016
2012016
Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3
JS Ross, M Fakih, SM Ali, JA Elvin, AB Schrock, J Suh, JA Vergilio, ...
Cancer 124 (7), 1358-1373, 2018
1832018
Genomic profiling of small-bowel adenocarcinoma
AB Schrock, CE Devoe, R McWilliams, J Sun, T Aparicio, PJ Stephens, ...
JAMA oncology 3 (11), 1546-1553, 2017
1822017
Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients
AP Garner, JM Gozgit, R Anjum, S Vodala, A Schrock, T Zhou, C Serrano, ...
Clinical Cancer Research 20 (22), 5745-5755, 2014
1722014
Pulmonary sarcomatoid carcinomas commonly harbor either potentially targetable genomic alterations or high tumor mutational burden as observed by comprehensive genomic profiling
AB Schrock, SD Li, GM Frampton, J Suh, E Braun, R Mehra, SC Buck, ...
Journal of Thoracic Oncology 12 (6), 932-942, 2017
1582017
Pan-cancer landscape and analysis of ERBB2 mutations identifies poziotinib as a clinically active inhibitor and enhancer of T-DM1 activity
JP Robichaux, YY Elamin, RSK Vijayan, MB Nilsson, L Hu, J He, F Zhang, ...
Cancer Cell 36 (4), 444-457. e7, 2019
1562019
Systemet kan inte utföra åtgärden just nu. Försök igen senare.
Artiklar 1–20